Article

CyanoCapture and Persist AI are collaborating to construct the first GMP manufacturing facility combining cyanobacteria culture with AI-driven robotics, set to be operational by Q4 2026 in the San Francisco Bay Area. This facility will facilitate the clinical-scale production of novel oral protein and peptide drugs, addressing the challenge of delivering these biologics orally.

The project will utilize CyanoCapture's cyanobacterial platform and Persist AI's robotic systems for formulation development and production optimization. Initial efforts will focus on converting injectable biologics into oral formulations, utilizing machine learning for enhanced research and development.